Cambrex Corporation (NYSE:CBM) opened at 58.25 on Friday. The stock had a trading volume of 80,894 shares. Advisors Asset Management Inc. purchased a new position in shares of Cambrex Corporation during the second quarter worth about $216,000. The stock was sold at an average price of $52.02, for a total transaction of $1,170,450.00. Adjusted EPS increased 22% to $1.23 compared to $1.01 in the same quarter a year ago. The company had revenue of $99.90 million for the quarter, compared to the consensus estimate of $96.07 million. Cambrex Corporation had a net margin of 13.24% and a return on equity of 24.11%.
Headquartered in East Rutherford, New Jersey, CBM recorded Net Revenue that rose 14% to $ 177.87 million from $ 156.19 million in the same quarter past year. First Analysis raised Cambrex Corporation from an "equal weight" rating to an "overweight" rating and set a $54.00 target price on the stock in a report on Monday, November 7th. During the same quarter in the previous year, the business posted $1.01 EPS. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
02/11/2016 - Cambrex Corporation had its "buy" rating reiterated by analysts at Singular Research.
Several company insiders have filed Insider transactions, on Dec 15, 2016, Shawn Cavanagh (EVP & COO) sold 30,000 shares at $53.58 per share price. The company's quarterly revenue was up 13.9% on a year-over-year basis. Company insiders own 2.63% of the company's stock. On average, analysts expect that Cambrex Corporation will post $2.70 earnings per share for the current year.
WARNING: "Cambrex Corporation (CBM) Sees Large Increase in Short Interest" was originally published by Community Financial News and is the property of of Community Financial News.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The Company's manufacturing facilities are located in the Europe and the United States. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.